SCHEMBL22438726

SCHEMBL22438726

COc1ccc(Cn2c(C)nc3c(Cl)ccnc32)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 5/20 0.54
PDE10A Q9Y233 1/20 0.53
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
MAPT P10636 2/20 0.48
ALOX15 P16050 1/20 0.48
HTR6 P50406 4/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
TP53 P04637 2/20 0.45
MDM4 O15151 1/20 0.45
MDM2 Q00987 1/20 0.45
PDE1B Q01064 2/20 0.44
PDE1A P54750 1/20 0.44
PDE1C Q14123 1/20 0.44
LMNA P02545 2/20 0.42
CNR2 P34972 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451833 0.82 PDE10A (0.61) DCTPP1PDE10AKDM4EALDH1A1MAPT
SCHEMBL4754879 0.79 HTR6 (0.40) DCTPP1PDE10AKDM4EALDH1A1HTR6
SCHEMBL22270343 0.76 MAPT (0.51) DCTPP1KDM4EALDH1A1MAPTALOX15
SCHEMBL20774516 0.76 HPGD (0.54) ALDH1A1CNR2L3MBTL1KMT2A
SCHEMBL30552245 0.76 HPGD (0.54) ALDH1A1CNR2L3MBTL1KMT2A
SCHEMBL18614407 0.75 PDE8B (0.51) KDM4EALDH1A1MAPTALOX15TP53
SCHEMBL5466105 0.73 PDE10A (0.55) DCTPP1PDE10AKDM4EALDH1A1MAPT
SCHEMBL29177117 0.73 MAPT (0.50) KDM4EALDH1A1MAPTALOX15PTGDR2
SCHEMBL30061820 0.73 MAPT (0.50) KDM4EALDH1A1MAPTALOX15PTGDR2
SCHEMBL6949121 0.73 HTT (0.53) KDM4EALDH1A1MAPTTP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11739098-B2 Substituted indole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-29 US disclosed
EP-3710440-B1 SUBSTITUTED INDOLE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2023-04-05 EP disclosed
US-20230098244-A1 SUBSTITUTED INDOLE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2023-03-30 US disclosed
US-20210253593-A1 SUBSTITUTED INDOLE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-08-19 US disclosed
EP-3710440-A1 SUBSTITUTED INDOLE COMPOUNDS Bristol-Myers Squibb Company (US) 2020-09-23 EP disclosed
CN-111448190-A Substituted indole compounds 百时美施贵宝公司 2020-07-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230098244-A1 SUBSTITUTED INDOLE COMPOUNDS TLR7, TLR1, HTR7 DCTPP1 4847/4885PDE10A 2307/4885KDM4E 2026/4885
US-20210253593-A1 SUBSTITUTED INDOLE COMPOUNDS TLR7, TLR1, HTR7 DCTPP1 4847/4885PDE10A 2307/4885KDM4E 2026/4885
US-11739098-B2 Substituted indole compounds TLR7, TLR1, HTR7 DCTPP1 4847/4885PDE10A 2307/4885KDM4E 2026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.